This is particularly pertinent to patients with advanced prostate cancer, who are currently treated with hormone-deprivation therapies (ADT) and/or drugs interfering with either the transcriptional activity of the androgen receptor (AR), referred to as (ARIs), or the synthesis of androgens. This evidence concerns the gene AR and Familial prostate cancer.